Tag Archive for: preclinical

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at European Society of Cardiology Congress 2023

/in

Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function Oslo, Norway – 29 August 2023 – Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and […]

Read more

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

/in

Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development  Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Read more…

Read more

Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Indication for its H-Guard® Technology

/in

Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology. Read more…

Read more

Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

/in

Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase […]

Read more